Inhibition of histone deacetylases in inflammatory bowel diseases

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 426-433

  Glauben, Rainer ^a   Siegmund, Britta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; AZOXYMETHANE; DEXTRAN SULFATE; GIVINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; MICRORNA; NITROBENZENE DERIVATIVE; STAT3 PROTEIN; SYNAPTOTAGMIN I; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL COMPOSITION; CELL POPULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DISEASE COURSE; ENTERITIS; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; HELPER CELL; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LAMINA PROPRIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN; TH1 CELL; TH17 CELL; TH2 CELL; TRANSCRIPTION REGULATION; TUMOR VOLUME;

ANIMALS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INFLAMMATORY BOWEL DISEASES; MICE;

EID: 79957944138     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00069     Document Type: Article

References (81)

1. Mathew CG. (2008) New links to the pathogene-sis of Crohn disease provided by genome-wide association scans. Nat. Rev. Genet. 9:9-14.
2. Baumgart DC, Carding SR. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627-1640.
3. Soderlund S, et al. (2009). Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterol-ogy. 136:1561-1567.
4. Karin M, Greten FR. (2005) NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749-759.
5. Tarmin L, et al. (1995) Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 55:2035-2038.
6. Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353-362.
7. Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 325:834-840.
8. Norris KL, Lee JY, Yao T P. (2009) Acetylation goes global: the emergence of acetylation biology. Sci. Signal. 2:pe76.
9. Spange S, Wagner T, Heinzel T, Kramer OH. (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41:185-198.
10. Fuss IJ, et al. (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:1490-1497.
11. Fuss IJ, et al. (1996) Disparate CD4+ lamina pro-pria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261-1270.
12. Stuber E, Strober W, Neurath M. (1996) Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183:693-698.
13. Weaver CT, Hatton RD, Mangan PR, Harrington LE. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821-52.
14. Acosta-Rodriguez EV, Napolitani G, Lanzavec-chia A, Sallusto F. (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942-9.
15. Zhang X, et al. (2011) Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect. Immun. 79:527-41.
16. Zhou L, et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967-74.
17. Fujino S, et al. (2003) Increased expression of in-terleukin 17 in inflammatory bowel disease. Gut. 52:65-70.
18. Fuss IJ, et al. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12:9-15.
19. Umetsu DT, DeKruyff RH. (1997) Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Proc. Soc. Exp. Biol. Med. 215:11-20.
20. Bouma G, Strober W. (2003) The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521-33.
21. Heller F, et al. (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that af-fects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 129:550-64.
22. Stephens GL, Shevach EM. (2007) Foxp3+ regulatory T cells: selfishness under scrutiny. Immunity. 27:417-9.
23. Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8:457-62.
24. Ruemmele FM, Brousse N, Goulet O. (2004) Autoimmune enteropathy: molecular concepts. Curr. Opin. Gastroenterol. 20:587-91.
25. Ochs HD, Gambineri E, Torgerson TR. (2007) IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38:112-21.
26. McDonel P, Costello I, Hendrich B. (2009) Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. Int. J. Biochem. Cell Biol. 41:108-16.
27. Grozinger CM, Hassig CA, Schreiber SL. (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U. S. A. 96:4868-73.
28. Feng Q, Zhang Y. (2001) The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15:827-832.
29. Chang S, Collins PL, Aune TM. (2008) T-bet dependent removal of Sin3A-histone deacetylase complexes at the Ifng locus drives Th1 differentiation. J. Immunol. 181:8372-81.
30. Chen GY, Osada H, Santamaria-Babi LF, Kannagi R (2006) Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 103:16894-9.
31. Sarra M, Pallone F, Macdonald TT, Monteleone G. (2010) IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 16:1808-13.
32. Edens RE, Dagtas S, Gilbert KM. (2006) Histone deacetylase inhibitors induce antigen specific energy in lymphocytes: a comparative study. Int. Immunopharmacol. 6:1673-81.
33. Moreira JM, Scheipers P, Sorensen P. (2003) The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer. 3:30.
34. Matsuoka H, Fujimura T, Mori H, Aramori I, Mutoh S. (2007) Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol. 7:1422-32.
35. Koenen HJ, et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 112:2340-52.
36. Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug. Discov. 8:969-81.
37. Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13:1299-307.
38. Wang L, Tao R, Hancock WW. (2009) Using his-tone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol. Cell Biol. 87:195-202.
39. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 138:583-94.
40. Bosisio D, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84:1540-8.
41. Jung ID, et al. (2009) Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int. J. Immunopathol. Pharmacol. 22:501-15.
42. Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 109:1123-30.
43. Sun Y, et al. (2009) Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 182:5899-903.
44. Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562-73.
45. Aung HT, et al. (2006) LPS regulates proinflam-matory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 20:1315-27.
46. Deng WG, Zhu Y, Wu KK. (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 103:2135-42.
47. Ito K, et al. (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203:7-13.
48. Maa MC, et al. (2010) Butyrate reduced lipopolysaccharide-mediated macrophage migration by suppression of Src enhancement and focal adhesion kinase activity. J. Nutr. Biochem. 21:1186-92.
49. Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718-28.
50. Choi Y, et al. (2008) Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp. Mol. Med. 40:574-81.
51. Lal G, et al. (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methy-lation. J. Immunol. 182:259-273.
52. Polansky JK, et al. (2008) DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38:1654-63.
53. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66:1277-81.
54. Schickel R, Boyerinas B, Park SM, Peter ME (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27:5959-74.
55. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. (2008) MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9:839-45.
56. Faraco G, et al. (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol. Dis. 36:269-79.
57. Kiernan R, et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758-66.
58. Greten FR, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-96.
59. Shibata W, et al. (2007) Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 179:2681-5.
60. Nenci A, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446:557-61.
61. Chen L, Fischle W, Verdin E, Greene WC. (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 293:1653-7.
62. Ashburner BP, Westerheide SD, Baldwin AS Jr. (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065-77.
63. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 66:5409-18.
64. Liu H, et al. (2006) Trichostatin A regulates hGCN5 expression and cell cycle on daudi cells in vitro. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26:534-7.
65. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J. Biol. Chem. 281:5612-22.
66. Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613-622.
67. Kramer OH, et al. (2006) Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 20:473-485.
68. Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015-22.
69. Marks PA, Dokmanovic M. (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs. 14:1497-511.
70. Bertrand P. (2010) Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem. 45:2095-116.
71. Reilly CM, et al. (2008) The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31:123-30.
72. Saouaf SJ, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen- induced arthritis. Exp. Mol. Pathol. 87:99-104.
73. Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1-15.
74. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281-90.
75. Boirivant M, Fuss IJ, Chu A, Strober W. (1998) Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to in-terleukin 4. J. Exp. Med. 188:1929-39.
76. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-8.
77. Neurath MF, et al. (2001) Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22:21-6.
78. Lugering A, et al. (2001) Infliximab induces apo-ptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 121:1145-57.
79. Tanaka T, et al. (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94:965-73.
80. Hegazi RA, et al. (2003) Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm. Bowel Dis. 9:230-36.
81. Chateauvieux S, Morceau F, Dicato M, Diederich M. (2010) Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010:479364.